LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) has secured a $15 million private equity placement from the Swiss investment boutique “FirmInvest AG,” whose principals are longstanding shareholders of CVBT. The contract is for 15 million shares of common stock at $1.00 each. No warrants or dilutive securities will be issued in connection with the private placement and the private placement does not provide for registration rights.
